Seeking Alpha

pharmaguy

pharmaguy
Send Message
View as an RSS Feed
View pharmaguy's Comments BY TICKER:
Latest  |  Highest rated
  • French plan to allow generics alarms Big Pharma [View news story]
    Here is the link to marketed biosimulars.

    http://bit.ly/QhP2Fo
    Apr 12 06:00 PM | Likes Like |Link to Comment
  • French plan to allow generics alarms Big Pharma [View news story]
    A lot of misinformation is being posted here. The regulatory path for biosimulars already exists in the EU and there are already 20 biosimulars that being marketed in there.
    It's the FDA that's lagging behind.

    Http://http://bit.ly/QhP2Fo
    Apr 12 05:59 PM | Likes Like |Link to Comment
  • AbbVie - Strong Product Pipeline Is Defining Its Future [View article]
    One more thing. If you do not believe biosimilar Humira is close to being a reality. Read this.

    http://bit.ly/1hqzlGr
    Apr 11 01:40 PM | Likes Like |Link to Comment
  • AbbVie - Strong Product Pipeline Is Defining Its Future [View article]
    Tom246
    Both of your statements are not correct.

    The companies who will produce biosimilars (eg Amgen, Novartis and AbbVie itself) all have years of experience making biologics. This is not new technology to them and no new facilities will have to be built. Toxicity is actually less of a problem with biosimilars then it is with small molecules.

    Biosimilar Enbrel is already a being sold all of the world outside of the US.

    Apr 11 01:33 PM | Likes Like |Link to Comment
  • AbbVie - Strong Product Pipeline Is Defining Its Future [View article]
    Nope that was not true with Humira.
    Humira had a clear profile advantage over the other drugs.
    There are no other near term major drugs in the pipeline.
    Apr 11 11:32 AM | 1 Like Like |Link to Comment
  • AbbVie - Strong Product Pipeline Is Defining Its Future [View article]
    The point is that the Abbvie combo has no advantage over either the Giliad or Merck drug. So abbvie has only 1.5 year period to sell it. This is hardly the block buster that the company was counting on.
    Apr 10 09:48 PM | 1 Like Like |Link to Comment
  • AbbVie - Strong Product Pipeline Is Defining Its Future [View article]
    I think you picked the wrong time to buy. Merck's HCV result is devastating to AbbVie. The pipeline looks much weaker today.
    Apr 10 01:25 PM | Likes Like |Link to Comment
  • AbbVie - Strong Product Pipeline Is Defining Its Future [View article]
    Anyone who thinks that there won't be biosimilars of the best selling drug in the world are just fooling themselves. As dis680 stated, Amgen and several other companies are now gearing up to make their own biosimilar version of Humira. Abbvie is also getting in this game and will make biosimilars of other company's products.
    Apr 9 02:42 AM | Likes Like |Link to Comment
  • Plenty Of Room For Everyone In The Race To FDA Approval For New Hepatitis C Therapies [View article]
    I would be very wary about any company pursuing RNAi based drugs.
    It's a sink hole that lots of companies have pursued with very little success.
    Jul 25 06:07 PM | Likes Like |Link to Comment
  • Plenty Of Room For Everyone In The Race To FDA Approval For New Hepatitis C Therapies [View article]
    I don't know a whole lot about AEMD's technology, but reducing viral load by 50% does not sound so great. Maybe there is more to it then just this.
    Jul 24 05:40 PM | 1 Like Like |Link to Comment
  • How Bad Will The Partial Hold On Sovaprevir Be For Achillion? [View article]
    Yes and there is nothing currently in sovapreveir's profile that would make you think they that Achillion could convince docs to prescribe this over the Gilead compound which will have a two year head start. Things could change when new trials are completed but right now future prospects do not look good.
    Jul 11 10:35 AM | Likes Like |Link to Comment
  • How Bad Will The Partial Hold On Sovaprevir Be For Achillion? [View article]
    I think is is pretty much over for sovaprevir. Yes it may be approved, but can someone tell me why a doctor would ever prescribe it. It's going to be really hard to beat both Gilliad's and AbbVie's HCV drug efficay profiles and they have yet to see any safety issues. I think Achillion's only hope is that all of the competors drugs do not have clean safety profiles or there will very little way to market this drug.
    Jul 11 07:20 AM | Likes Like |Link to Comment
  • The Ulcerative Colitis Game Of Thrones [View article]
    Interesting discussion guys, but this has really little to do with what the author's article is about, new UC treatments.
    May 25 12:25 AM | 1 Like Like |Link to Comment
  • 3 Pharmaceuticals For Attractive Dividends [View article]
    Your analysis on Abbott is really wrong. Humira is with ABBV not ABT. Abbott is no longer a non-generic Pharma company and so patent expiration is a concern for ABBV not ABT.
    May 15 01:08 PM | Likes Like |Link to Comment
  • Assessing The Dividend Growth Potential For The New Abbott [View article]
    Alex2322,

    Abbott is no longer a drug company and they are not developing new drugs. Both companies are now in totally different areas of the Health care market. Abbv growth totally depends on developing new drugs and expanding use of existing drugs. Both are an iffy proposition. Abbott growth will come from expanding their product into emerging markets. These are two really different things and not directly comparable.
    Mar 4 11:51 AM | Likes Like |Link to Comment
COMMENTS STATS
95 Comments
54 Likes